Trials / Unknown
UnknownNCT03151382
A Based on PEEG and PET Study of Anxiolytic Treatment to Improve Cognitive Function in Patients With Alzheimer Disease
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Zhejiang Provincial People's Hospital · Academic / Other
- Sex
- All
- Age
- 55 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Objective: Evaluation the improvement of the cognitive function of tandospirone add-on treatment on patients with AD comorbid anxiety. Number of Patients: 30 Methodology: Randomized, open-label, parallel-group Assigned Interventions: Experimental: Tandospirone, 30-60 mg/d + Donepezil, 10 mg/d; Control group: Donepezil, 10 mg/d. Effect Evaluation: Primary Outcome: Change from baseline in ADAS-cog total score at week 12; NPI scale total score at week 12;
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tandospirone Citrate | Tandospirone, 30-60 mg/d |
| DRUG | Donepezil Hydrochloride | Donepezil, 10 mg/d |
Timeline
- Start date
- 2017-05-20
- Primary completion
- 2017-12-31
- Completion
- 2018-06-30
- First posted
- 2017-05-12
- Last updated
- 2017-05-12
Source: ClinicalTrials.gov record NCT03151382. Inclusion in this directory is not an endorsement.